ZBIO

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on April 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted an aggregate of 41,475 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4)

SCHEDULE 13D/A - Zenas BioPharma, Inc. (0001953926) (Subject)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)

424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)

FWP - Zenas BioPharma, Inc. (0001953926) (Subject)

FWP - Zenas BioPharma, Inc. (0001953926) (Subject)

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offerin

424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)

424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)

FWP - Zenas BioPharma, Inc. (0001953926) (Subject)

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and shares of its common stock (the "Equity Offering"). In addition, Zenas intends to grant the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an add

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on March 16, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 235,700 shares of the Company's common stock ("Stock Options") and an aggregate of 33,450 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an induce

DEFA14A - Zenas BioPharma, Inc. (0001953926) (Filer)

DEF 14A - Zenas BioPharma, Inc. (0001953926) (Filer)

S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

10-K - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 - - New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development - - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 - - Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data b

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 35,700 shares of the Company's common stock ("Stock Options") and an aggregate of 53,625 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an induc

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)